BTIG analyst Mark Massaro reiterated a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) yesterday and set a price target of $13.00. The company’s shares closed last Friday at $8.89.
Massaro covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Exact Sciences, and CareDx. According to TipRanks, Massaro has an average return of -4.7% and a 39.72% success rate on recommended stocks.
Currently, the analyst consensus on Adaptive Biotechnologies is a Hold with an average price target of $11.13.
See the top stocks recommended by analysts >>
ADPT market cap is currently $1.27B and has a P/E ratio of -5.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Read More on ADPT:
- Natera named top pick in minimal residual disease at Piper Sandler
- Adaptive price target lowered to $7.50 from $12 at Piper Sandler
- Adaptive Biotechnologies partners with Epic to increase access to MRD monitoring
- Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
- Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
